Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 4M | 5M | 4M | 139K | 186K |
| Gross Profit | -404K | 1M | 696K | -961K | -1M |
| Operating Income | -8M | -8M | -4M | -5M | -4M |
| EBITDA | -10M | -6M | -6M | -2M | -3M |
| Net Income | -11M | -7M | -7M | -3M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0051
+0.00% today
1Y Change
-82.22%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
StageZero Life Sciences Ltd. (SZLSF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 82.2% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -25.1%, EPS growth of -10.0%, a dividend yield of 0.0%. What stands out right now is revenue -25.1%, EPS -10.0%, free cash flow +61.2% with operating margin -204.1% and ROIC 151.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SZLSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SZLSF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SZLSF Max Drawdown
-98.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SZLSF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$185.9K
+34.0% YoY
FY Net Income
-$3.9M
-13.3% YoY
Free Cash Flow
-$3.3M
+28.9% YoY
Revenue Growth
-25.1%
EPS Growth
-10.0%
Gross Margin
-10.6%
Net Margin
-300.8%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 4M | 5M | 4M | 139K | 186K |
| Gross Profit | -404K | 1M | 696K | -961K | -1M |
| Operating Income | -8M | -8M | -4M | -5M | -4M |
| EBITDA | -10M | -6M | -6M | -2M | -3M |
| Net Income | -11M | -7M | -7M | -3M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 16K | 2M | 7M | 71K | 106K |
| Total Assets | 701K | 11M | 9M | 2M | 2M |
| Total Liabilities | 8M | 8M | 10M | 6M | 7M |
| Shareholder Equity | -8M | 3M | -1M | -4M | -5M |
| Total Debt | 2M | 1M | 4M | 2M | 3M |
| Net Debt | 2M | -369K | -3M | 2M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+28.3% YoY
Capital Expenditures
3K
+93.7% YoY
Free Cash Flow
3M
+28.9% YoY
Key ratios
Gross Margin
-10.6%
Operating Margin
-204.1%
Net Margin
-300.8%
ROE
481.5%
Debt / Equity
-0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.